AXGN Axogen Inc.

Axogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020

Axogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020
EN
08/10/2020

Underlying

AXGNAxogen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Axogen Inc.

 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences: Jefferies Global Healthcare Conference (London)Participation: Fireside chat and 1x1 investor meetingsDate/Time: Fireside Chat Tuesday, November 18, 2025, 4:30 PM GMTWebcast Link:  Canaccord Genuity MedTech...

November 4, 2025 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Axogen, Inc. Reports Third Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a ...

October 29, 2025 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October...

Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 third quarter financial results on Wednesday, October 29, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the con...

October 15, 2025 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences ALACHUA, Fla. and TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in four upcoming investor conferences: Cantor Global Healthcare Conference (NYC)Participation: Fireside chat and 1x1 investor meetings Date/Time: Fireside Chat Wednesday, September 3, 2025, 3:20 PM ETWebcast Link: Wells Fargo Healthcare Confere...

August 27, 2025 1 EN
 PRESS RELEASE
Free
AXGN AXOGEN INC.

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft FDA PDUFA goal date extended by three months ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025. On August 22, 2025, the Company received a communication from the FDA indicating that the information submitted by the Company in response to an FD...

August 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch